Brander, D. M., Beaven, A. W., Gockerman, J. P., Diehl, L. F., Gasparetto, C., Shea, T. C., … Rizzieri, D. A. (2012). Phase II Study of VEGF Inhibitor, PTK787/ZK222584, in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma. In Blood (Vol. 120, pp. 1626–1626). American Society of Hematology. https://doi.org/10.1182/blood.v120.21.1626.1626

Brander, Danielle M., Anne W. Beaven, Jon P. Gockerman, Louis F. Diehl, Cristina Gasparetto, Thomas C. Shea, Carlos deCastro, Joseph O. Moore, and David A. Rizzieri. “Phase II Study of VEGF Inhibitor, PTK787/ZK222584, in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma.” In Blood, 120:1626–1626. American Society of Hematology, 2012. https://doi.org/10.1182/blood.v120.21.1626.1626.

Brander DM, Beaven AW, Gockerman JP, Diehl LF, Gasparetto C, Shea TC, et al. Phase II Study of VEGF Inhibitor, PTK787/ZK222584, in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma. In: Blood. American Society of Hematology; 2012. p. 1626–1626.

Brander, Danielle M., et al. “Phase II Study of VEGF Inhibitor, PTK787/ZK222584, in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma.” Blood, vol. 120, no. 21, American Society of Hematology, 2012, pp. 1626–1626. Crossref, doi:10.1182/blood.v120.21.1626.1626.

Brander DM, Beaven AW, Gockerman JP, Diehl LF, Gasparetto C, Shea TC, deCastro C, Moore JO, Rizzieri DA. Phase II Study of VEGF Inhibitor, PTK787/ZK222584, in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma. Blood. American Society of Hematology; 2012. p. 1626–1626.